Expert Details
Pharmaceutical Imaging, Biological, Physical and Analytical Research, Pharma Commercial Viability
ID: 725156
North Carolina, USA
He worked through technology, regulatory, and commercial failures. He built businesses from no technology to ultimately having product. He raised capital via public markets and business deals.
He in-licensed technology from inventors, universities, and companies. He developed corporate deal structures that were joint ventures, licenses, and development & marketing overseas. He interacted with a wide range of US and Foreign companies seeking partnerships. The companies which he ran as CEO benefited from these activities via fees obtained from the partnerships. The companies he ran also benefited via acquisition of products to enhance the companies portfolios.
He built companies and licenses or purchased technology to develop. He reviewed numerous drug technologies to finally identify the products to be acquired. These product were evaluated for commercial value, likelihood of gaining an approval, and cost of development. He also ran research for a government laboratory and in a small biotechnology company. The areas he gained experience for drug activities were: anti-infective, anti-inflammation, cancer, septic shock, plasma expanders, blood substitutes, gastroenterology, pharmaceutical medical imaging (cardiovascular), and others. His exposure to these areas provided a significant understanding of drugs in general and the activities required to make and sell drugs.
He recreated businesses and technologies in failing companies. In the technology area, he filed and received more than 10 patents. He has a number of patents pending.
In the business space, he work to find ways of accomplishing goals that fit with the business. Often this requires attempting activities that are new and innovative.
He also advise entrepreneurs, scientists, research staff, and business executives on innovative ways of achieving goals.
Array
He worked with a wound healing company to advise the CEO. As a direct result, the company being advised restructured its patent portfolio and filed new patents, they redesigned clinical trials, they with drew the earlier submission of a registration statement to go public and conducted a private placement, they redesigned the therapeutic area of the company to be more compatible to raising capital. The company is now running 3 Phase 2 clinical studies where success in any one will likely make them fundable in an IPO.He assisted a not-for-profit to develop a business plan for an education unit. The not-for-profit won an award for the plan and they are now implementing the plan as a business.He worked with a not-for profit to develop new patents for treatment of cancer. The activity resulted in new patent filings and there is now interest from a small company in licensing the patents.He worked with a state senator and not-for-profit to bring a large team from industry together to explore joint development of computer personal medical records. This was a large effort which lead to program grants being filed.
Education
| Year | Degree | Subject | Institution |
|---|---|---|---|
| Year: 1978 | Degree: Postdoctoral Fellow | Subject: Biochemistry | Institution: University of Michigan |
| Year: 1976 | Degree: Postdoctoral Fellow | Subject: Biochemistry | Institution: University of South Carolina |
| Year: 1975 | Degree: Ph.D. | Subject: Biochemistry | Institution: University of South Carolina |
| Year: 1971 | Degree: B.S. | Subject: Chemistry | Institution: University of Notre Dame |
Work History
| Years | Employer | Title | Department |
|---|---|---|---|
| Years: 2005 to Present | Employer: Undisclosed | Title: President & Chief Executive Officer & Director & Founder | Department: |
Responsibilities:Founded company with a business focused on building and increasing value of early stage companies or technology. |
|||
| Years | Employer | Title | Department |
| Years: 2005 to Present | Employer: Undisclosed | Title: Chairman of the Board | Department: |
Responsibilities:Chair the Board of a not-for-profit company affiliated with the American Nutritional Society. |
|||
| Years | Employer | Title | Department |
| Years: 2000 to 2005 | Employer: IMCOR Pharmaceutical Co. | Title: President & Chief Executive Officer, & Director | Department: |
Responsibilities:Re-engineered and re-built the company into a complete operational business resulting in a launch of a pharmaceutical imaging product. Photogen became IMCOR (name change) to reflect the new direction of the business.Conducted test market launch of product, closed deal in Japan ($10MM in milestones, royalty plus transfer cost on product), cut acquisition debt (50%), reduced burn, identified myocardial perfusion method to eliminate stress exam, closed on PIPE for $10MM. Purchased FDA approved product, manufacturing facility, and operational organization (for less than 1/10th of the actual development expense). Resolved $40MM debts for seller in the process of the purchase. Launched the product. Debt financing obtained for $11MM. Built infrastructure to manage pharmaceutical imaging business. Raised $12MM in new financing while simplifying the capital structure. Reviewed original team and technologies. Restructured the team, eliminated inventor conflicts on patents, and filed patents on new discovery in the imaging space. New imaging discovery allowed for redirection of the company into medical imaging space. |
|||
| Years | Employer | Title | Department |
| Years: 1997 to 1999 | Employer: INKINE PHARMACEUTICAL CO., INC. | Title: President & Chief Operating Officer & Director & Founder | Department: |
Responsibilities:Played key role in raising $17 MM to finance the operation. Panax became InKine (post financing). InKine was launched with three years of cash. Market capitalization of Panax went from $2-4 MM (1995) to $30-40 MM for InKine (1998) with increase of 400% in stock price.Led business development, directed discovery research, oversaw manufacturing and facilities. Technology applications included purgative, laxative, autoimmune, cancer, inflammation, asthma and allergy. Instrumental in developing Diacol (purgative) as a commercially viable opportunity. Expected product launch in 2000. Worked with new CEO to rebuild the management team and Board of Directors. |
|||
| Years | Employer | Title | Department |
| Years: 1995 to 1997 | Employer: PANAX PHARMACEUTICAL CO. LTD | Title: Chairman, President & Chief Executive Officer & Director | Department: |
Responsibilities:Turned around moribund public bio-pharmaceutical company within two years. Company’s initial focus was the identification of new chemical entities from natural sources. Operations included international experience. Extensive business development, financial responsibility and SEC reporting. |
|||
| Years | Employer | Title | Department |
| Years: 1992 to 1995 | Employer: MAGAININ PHARMACEUTICALS INC. | Title: Vice President | Department: Research |
Responsibilities:Directed research on new classes of pharmacological agents for topical and systemic use, including anti-infectives, wound healing, oral health care, septic shock, cancer, and sexually transmitted diseases.Managed oral health care project through selection of lead compound and evaluation by corporate partner. Led antifungal research to selection of topical lead compound for women's health care and dermatological use. Presented data to potential corporate partners for licensing consideration. Developed program for prevention of sexually transmitted diseases and demonstrated proof of concept. Coordinated chemical and biological manufacturing scale up through selection of contract manufacturer and initial pilot plant evaluations. Coordinated cancer research between Magainin and corporate partner. Identified three compounds with systemic activities against melanoma. Prepared and presented research to potential corporate sponsors, stock analysts, and investors. |
|||
| Years | Employer | Title | Department |
| Years: 1978 to 1992 | Employer: NAVAL MEDICAL RESEARCH INSTITUTE | Title: Director/Principal Investigator | Department: Septic Shock Research Program |
Responsibilities:Directed/oversaw basic and applied research, in gram-negative sepsis and septic shock research in surgery, pulmonology, critical care, pathology, physiology, microbiology, biochemistry, immunology and molecular biology. Served on Institute Scientific Advisory Board. Committee assignments included; science review, overhead budget reduction, personnel policy, public relations, and military organization.Constructed, organized, and led multi-disciplinary program in septic shock. Budgeted and obtained $2M/year funding. Awarded Civil Service Achievement award. Identified new strategy to prevent shock and Adult Respiratory Distress Syndrome and formed strategic alliance with corporation. Filed seven patents. Developed artificial blood and liposome programs and obtained and budgeted $1M/year funding. Key member on three person team to reduce institute overhead 20% and on ten person team to convert institute from line to matrix organization. |
|||
| Years | Employer | Title | Department |
| Years: 1976 to 1978 | Employer: UNIVERSITY OF MICHIGAN | Title: Postdoctoral Fellow | Department: |
Responsibilities:Kinetic and thermodynamic studies on carbohydrate receptor interactions. Developed new class of surfactants. Seven publications. |
|||
Government Experience
| Years | Agency | Role | Description |
|---|---|---|---|
| Years: 1978 to 1992 | Agency: Naval Medical Research Institute | Role: Director of Septic Shock Research Program | Description: He led a team of more than 50 people to conduct research on treating combat casualties. The particular specialty was septic shock. |
International Experience
| Years | Country / Region | Summary |
|---|---|---|
| Years: 1995 to 1997 | Country / Region: Russia / St. Petersburg | Summary: He managed research research activities in drug discovery in a number of facilities in government labs in Russia. |
Career Accomplishments
| Awards / Recognition |
|---|
| NIH Postdoctoral Fellowship, 1977. Outstanding performance award nine consecutive years, 1982-1991. Naval Medical Research Institute "Most Significant Scientific Publication" 1985 and 1986. Civil Service Special Achievement Award for restructuring research activities, 1986. |
| Publications and Patents Summary |
|---|
| Author of eight patents, one invention registration, seven patent applications and 52 published articles. |
Fields of Expertise
business, initial public offering, joint venture, time-to-market, business development, drug, drug development, investigational drug, investigational drug procedures, pharmaceutical industry, pharmaceutical product development, pharmaceutical research, pharmacology, research and development, strategic research planning, innovation, pharmaceutical imaging, respiratory distress syndrome, capital structure, sexually transmitted infection, burn medicine, analytical research